Skip to Main Content
Phase III

Efficacy and Safety of WTX101 Administered for 48 Weeks Versus Standard of Care in Wilson Disease Subjects

  • Study HIC#:2000022372
  • Last Updated:07/15/2021

Wilson Disease (WD) is an autosomal recessive disorder of impaired copper (CU) transport caused by mutations in the ATP7B gene. WTX101 (bis-choline tetrathiomolybdate) is a first-in-class copper-protein-binding agent with a unique mechanism of action, under investigation as a novel therapy for WD. It is formulated as an enteric coated tablet (15 mg strength) for oral administration. The purpose of this study is to evaluate the efficacy of WTX101 administered for 48 weeks compared to standard of care (SOC) in WD subjects aged 18 and older.

  • Age12 years and older
  • GenderBoth
  • Start Date04/02/2018
  • End Date02/28/2021

Trial Purpose and Description

The primary objective is to evaluate the efficacy of WTX101 administered for 48 weeks, compared to standard of care (SoC), on copper (Cu) control in WD subjects aged 18 and older. Copper control will be assessed in terms of the percentage change from baseline (Day 1) to 48 weeks in non-ceruloplasmin-bound copper (NCC) levels. For WTX101-treated subjects, the NCC level will be corrected for the amount of Cu bound to the WTX101 tripartite complex (TPC)

Eligibility Criteria

Inclusion Criteria:

Subjects who meet all of the following criteria will be eligible to participate in the study:

  • Established diagnosis of WD by Leipzig-Score ≥4 documented by testing as outlined in the 2012 European Association for the Study of Liver WD Clinical Practice Guidelines;
  • Treatment for >28 days for WD with chelation therapy (ie, penicillamine, trientine hydrochloride), Zn therapy, or a combination of a chelator and Zn; OR Treatment naïve or treatment for ≤28 days for WD with chelation therapy (ie, penicillamine, trientine hydrochloride), Zn therapy, or a combination of a chelator and Zn;
  • Willing and able to give informed consent for participation in the study;
  • Male or female subjects, aged 18 years or older as of signing the informed consent form (ICF);
  • Able to understand and willing to comply with study procedures, restrictions, and requirements, as judged by the Investigator;
  • Willing to undergo ≥48-hour washout from current WD treatment;
  • Adequate venous access to allow collection of required blood samples;
  • Willing to avoid use of vitamins and/or minerals containing Cu, Zn, or Mo throughout the study duration;
  • Willing to avoid intake of foods and drinks with high contents of Cu throughout the study duration;
  • Females of childbearing potential will be included if they are either sexually inactive (abstinent) for 14 days prior to the first WTX101 dose and continuing through 28 days after the last WTX101 dose, or using 1 of the following highly effective birth control methods (ie, results in <1% failure rate when used consistently and correctly):
    1. Intrauterine device (without Cu) in place for at least 3 months prior to the first WTX101 dose and throughout the study;
    2. Surgical sterilization of the partner (vasectomy for 6 months minimum);
    3. Combined (estrogen or progestogen containing) hormonal contraception associated with the inhibition of ovulation (either oral, intravaginal, or transdermal) for at least 3 months prior to the first WTX101 dose and throughout the study;
    4. Progestogen only hormonal contraception associated with the inhibition of ovulation (either oral, injectable, or implantable) for at least 3 months prior to the first WTX101 dose and throughout the study;
    5. Intrauterine hormone releasing system for at least 3 months prior to the first WTX101 dose and throughout the study; or
    6. Bilateral tubal occlusion for at least 6 months prior to the first WTX101 dose;
      • Note: Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. In this trial, abstinence is only acceptable if in line with the subject's preferred and usual lifestyle; and
      • Note: Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhoea method are not acceptable methods of contraception. As well, female condom and male condom should not be used together;
  • Females of childbearing potential agree to remain sexually inactive or to keep the same birth control method for at least 28 days following the last dose;
  • A female of non-childbearing potential must have undergone 1 of the following sterilization procedures at least 6 months prior to the first WTX101 dose:
    1. Hysteroscopic sterilization;
    2. Bilateral tubal ligation or bilateral salpingectomy;
    3. Hysterectomy; or
    4. Bilateral oophorectomy; OR be postmenopausal with amenorrhoea for at least 1 year prior to the first WTX101 dose and follicle stimulating hormone serum levels consistent with postmenopausal status;
  • A non-vasectomized male subject agrees to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days beyond the last dose of study drug. For a vasectomized male who has had his vasectomy 6 months or more prior to study start, it is required that they use a condom during sexual intercourse. A male who has been vasectomized less than 6 months prior to study start must follow the same restrictions as a non-vasectomized male;
    • Note: Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. In this trial, abstinence is only acceptable if in line with the subject's preferred and usual lifestyle; and
    • Note: Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhoea method are not acceptable methods of contraception. As well, female condom and male condom should not be used together; and
  • If male, agrees not to donate sperm from the first WTX101 dose until 90 days after dosing.

Exclusion Criteria:

Subjects who meet any of the following criteria will be excluded from participation in the study:

  • Decompensated hepatic cirrhosis;
  • MELD score >13;
  • Modified Nazer score >7;
  • Clinically significant gastrointestinal bleed within past 3 months;
  • Alanine aminotransferase >2 × upper limit of normal (ULN) for subjects treated for >28 days with WD therapy (Cohort 1);
  • Alanine aminotransferase >5 × ULN for treatment naïve subjects or subjects who have been treated for ≤28 days (Cohort 2);
  • Marked neurological disease requiring either nasogastric feeding or intensive inpatient medical care;
  • Severe anaemia with a hemoglobin <9 g/dL;
  • Participation in a clinical study of an experimental or unapproved/unlicensed therapy at the same time or within the 4 weeks prior to this Screening Visit;
  • History of seizure activity within 6 months of study start;
  • Pregnant (or women who are planning to become pregnant) or lactating women;
  • Known sensitivity to WTX101, WTX101 excipients (anhydrous di-calcium phosphate, anhydrous sodium carbonate), or any of the ingredients contained in WTX101 or related compounds;
  • Active infection with hepatitis B virus (positive hepatitis B surface antigen) or C virus (subjects with positive hepatitis C antibody result would require confirmation of active disease with a positive hepatitis C polymerase chain reaction test), or seropositivity for human immunodeficiency virus;
  • Any disability acquired from trauma or another illness that, in the opinion of the Investigator, could interfere with evaluation of disability due to WD;
  • Previous treatment with tetrathiomolybdate;
  • Major systemic disease or other illness that would, in the opinion of the Investigator, compromise subject safety or interfere with the collection or interpretation of study results;
  • In the opinion of the Investigator, the subject is likely to be non-compliant or uncooperative during the study; or
  • Any deviation in laboratory values that are confirmed on re-examination to be clinically significant by the Investigator that would jeopardize the safety of the subject or impact the validity of the study results.

Principal Investigator

For more information about this study, contact:

Or contact the Help us Discover team on: